Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Liabilities (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 18.56% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 18.56% year-over-year, with the annual reading at $1.6 million for FY2025, 18.56% up from the prior year.
  • Other Non-Current Liabilities hit $1.6 million in Q4 2025 for Taysha Gene Therapies, down from $1.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $42.1 million in Q1 2024 to a low of $1.2 million in Q1 2025.
  • Historically, Other Non-Current Liabilities has averaged $7.4 million across 4 years, with a median of $3.5 million in 2022.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 952.17% in 2024 and later plummeted 97.15% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $4.1 million in 2022, then crashed by 61.82% to $1.6 million in 2023, then decreased by 16.99% to $1.3 million in 2024, then rose by 18.56% to $1.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for TSHA at $1.6 million in Q4 2025, $1.6 million in Q3 2025, and $1.4 million in Q2 2025.